Small Molecule · SYT-510

SYT-510

Oral, first-in-class selective endocannabinoid reuptake inhibitor (SERI) developed by Synendos Therapeutics, a Basel company spun out of the University of Bern. Per the company, SERIs mildly and selectively raise endogenous cannabinoid levels by inhibiting a newly identified target in the endocannabinoid system; Synendos's ECNP 2026 pharmacology poster identifies that target as the endocannabinoid membrane transporter ACSL4 isoform 2 and reports reversible inhibition of anandamide and 2-AG uptake with selectivity over CB1, CB2, FAAH, MAGL, ABHD6 and ABHD12. An EMA-authorised first-in-human single-ascending-dose study and a UK multiple-ascending-dose study in healthy volunteers were completed; the company reported no drug-related safety concerns, CNS exposure at the anticipated pharmacological levels, and an EEG effect consistent with anxiolytic medicines. A Phase 2a single-dose crossover experimental-medicine study in generalized anxiety disorder began dosing in 2026 with preliminary data guided for early 2027. Chemical structure has not been disclosed.

Also known as: SYT-510, SYT510, SYT 510

Key facts

Modality
Small molecule
Mechanism
ACSL4 inhibitor
Highest phase
Phase 2
Trials
2 tracked · 1 recruiting · 1 sites
Next catalyst
Early 2027 — Topline data (Generalized anxiety disorder)

Mechanism of action#

Selective endocannabinoid reuptake inhibitor (SERI). Synendos describes SYT-510 as a first-in-class inhibitor of a newly identified drug target in the endocannabinoid system that mildly and selectively increases endogenous cannabinoid levels with a self-limiting mode of action. The sponsor's ECNP 2026 preclinical characterization reports that SYT-510 binds the endocannabinoid membrane transporter ACSL4 isoform 2 and selectively, reversibly inhibits cellular uptake of anandamide (AEA) and 2-arachidonoylglycerol (2-AG), is selective against CB1R, CB2R, FAAH, MAGL, ABHD6 and ABHD12 and a CNS receptor/ion-channel panel, elicits CB1-mediated, ACSL4-dependent short-term synaptic plasticity in brain slices, and is active in rodent anxiety and compulsive-behaviour models without sedation or tolerance. In healthy volunteers, 14 days of dosing increased plasma 2-AG and produced a dose-dependent increase in EEG beta power. The clinical hypothesis is that raising endogenous cannabinoid tone produces anxiolysis without the cognitive impairment, sedation and abuse liability of direct CB1 agonists.

TargetActionAffinity
ACSL4primaryACSL4Inhibitor—ⓘ

Formulations#

FormulationRouteRegimenPharmacokinetics
SYT-510 oral formulation
Phase 2a (NCT07478744): a single oral dose in the morning with liquid, versus matching placebo, in a two-way crossover. Phase 1 (NCT06670950): two oral formulations (A and B) compared for relative bioavailability fasted, formulation A fed, then multiple ascending oral doses over 14 days in Part 2. Dose levels not publicly disclosed.
OralSingle dose—

Development timeline#

Jul 24Jan 25Jul 25Jan 26Jul 26Jan 27TodayPhase 124 Sept 2025 — readout (met) — Phase 1 SAD/MAD topline in healthy volunteers: no drug-related safety concerns, plasma and CNS exposure at anticipated pharmacological levels, EEG effect consistent with anxiolytic medicines.24 Sept 2025 — Phase 1 Results — Synendos reports positive Phase 1 topline results for SYT-51018 Jan 2024 — phase change — Synendos announced EMA authorisation to begin the Phase 1 first-in-human, randomized, double-blind, placebo-controlled single-ascending-dose study of SYT-510 in healthy adults. The SAD study is not registered on ClinicalTrials.gov and its first-dosing date is not disclosed, so this authorisation date is a lower bound for entry into Phase 1.Phase 231 Mar 2027 — upcoming — Preliminary data from the Phase 2a single-dose crossover study of SYT-510 in generalized anxiety disorder (amygdala fMRI response and defensive-behaviour endpoints), guided for early 2027.20 May 2026 — Trial started — Synendos starts dosing in Phase 2 trial of SYT-510 in generalized anxiety disorder22 Apr 2026 — phase change — Phase 2a NCT07478744 started (actual start date per ClinicalTrials.gov); Synendos publicly announced the start of dosing on 2026-05-20.
Phase change Readout Event UpcomingHover a marker for details.
Phase 2Apr 2026 – Mar 2027
  1. UpcomingPreliminary data from the Phase 2a single-dose crossover study of SYT-510 in generalized anxiety disorder (amygdala fMRI response and defensive-behaviour endpoints), guided for early 2027.↗
  2. Trial startedSynendos starts dosing in Phase 2 trial of SYT-510 in generalized anxiety disorder↗
  3. Phase 2a NCT07478744 started (actual start date per ClinicalTrials.gov); Synendos publicly announced the start of dosing on 2026-05-20.
Phase 1Jan 2024 – Sept 2025
  1. metPhase 1 SAD/MAD topline in healthy volunteers: no drug-related safety concerns, plasma and CNS exposure at anticipated pharmacological levels, EEG effect consistent with anxiolytic medicines.↗
  2. Phase 1 ResultsSynendos reports positive Phase 1 topline results for SYT-510↗
  3. Synendos announced EMA authorisation to begin the Phase 1 first-in-human, randomized, double-blind, placebo-controlled single-ascending-dose study of SYT-510 in healthy adults. The SAD study is not registered on ClinicalTrials.gov and its first-dosing date is not disclosed, so this authorisation date is a lower bound for entry into Phase 1.↗

SYT-510 for Generalized anxiety disorder#

Phase 2RecruitingGeneralized anxiety disorder indication →

SYT-510, an oral first-in-class selective endocannabinoid reuptake inhibitor, for generalized anxiety disorder (GAD) — Synendos Therapeutics' lead and only clinical program. After an EMA-authorised first-in-human single-ascending-dose study and a UK multiple-ascending-dose/relative-bioavailability study (NCT06670950, completed May 2025) in healthy volunteers, Synendos reported in September 2025 no drug-related safety concerns, CNS exposure at anticipated pharmacological levels and an EEG signature consistent with anxiolytics. The Phase 2a study NCT07478744 (SYN510CT-GAD201) started 2026-04-22 at South London and Maudsley in collaboration with Professor Allan Young and King's College London: up to 24 adults meeting DSM-5 GAD criteria receive a single oral dose of SYT-510 and placebo in a randomized, quadruple-masked two-way crossover, with primary outcomes of amygdala BOLD fMRI response to fearful stimuli and defensive behaviour on the Joystick Operated Runway Task, plus social avoidance. It is an experimental-medicine proof-of-mechanism study rather than a symptom-scale efficacy trial. The company guides preliminary data for early 2027. No designations are disclosed.

Readouts

  • Early 2027AnticipatedTopline dataNCT07478744

    Preliminary data from the Phase 2a single-dose crossover study of SYT-510 in generalized anxiety disorder (amygdala fMRI response and defensive-behaviour endpoints), guided for early 2027. ↗

  • 2025-09-24ReportedTopline datametNCT06670950

    Phase 1 SAD/MAD topline in healthy volunteers: no drug-related safety concerns, plasma and CNS exposure at anticipated pharmacological levels, EEG effect consistent with anxiolytic medicines. ↗

Clinical trials#

NCT07478744SYN510CT-GAD201Phase 2Recruitingn=24

A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder

Started Apr 2026· Primary completion Jan 2027· 1 site across 1 country

United Kingdom

NCT06670950SYN510CT02Phase 1Completedn=28

A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants

Started Nov 2024· Primary completion May 2025

Conference coverage#

SYT-510 appears in 2 CNS Pulse conference abstracts:

Sources#

  1. Maeder C, et al. Pharmacological characterization of SYT-510, a first-in-class selective endocannabinoid reuptake inhibitor. ECNP 2026, PS04-4032 — ECNP Congress 2026 (via CNS Pulse)
  2. NCT06670950 (SYN510CT02) — A Phase 1 Single Dose and Multiple Ascending Dose Study of SYT-510 in Healthy Participants — ClinicalTrials.gov (U.S. National Library of Medicine)
  3. NCT07478744 (SYN510CT-GAD201) — A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder — ClinicalTrials.gov (U.S. National Library of Medicine)
  4. Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for First-in-Class Endocannabinoid System Modulator SYT-510 (2024-01-18, wire copy) — Synendos Therapeutics AG (via MG Magazine)
  5. Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials Paving the Way for Phase 2 in Mental Health (2025-09-24, wire copy) — Synendos Therapeutics AG (via BioSpace)
  6. Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder (2026-05-20) — Synendos Therapeutics AG